ICRF 198

hydrolysis product of dexrazoxane; ADR-925 is the (S)-enantiomer of ICRF-198; structure given in first source; ADR 925 is identical to N,N'-((1S)-1-methyl-1,2-ethanediyl)-bis(N-(2-amino-2-oxoethyl))glycine

Also Known As:

ADR 925; ADR-925; ICRF 198, (+-)-isomer; ICRF-198; N,N'-((1S)-1-methyl-1,2-ethanediyl)-bis(N-(2-amino-2-oxoethyl))glycine

Networked: 7 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Hasinoff, Brian B: 2 articles (08/2003 - 01/2002)
2.	Brázdová, Petra: 1 article (01/2018)
3.	Bureš, Jan: 1 article (01/2018)
4.	Chládek, Jaroslav: 1 article (01/2018)
5.	Jirkovská, Anna: 1 article (01/2018)
6.	Jirkovský, Eduard: 1 article (01/2018)
7.	Karabanovich, Galina: 1 article (01/2018)
8.	Kovaříková, Petra: 1 article (01/2018)
9.	Lenčová, Olga: 1 article (01/2018)
10.	Pokorná, Zuzana: 1 article (01/2018)

Related Diseases

1.	Cardiotoxicity 01/01/2018 - "The aim of this study is to characterize the conversion and disposition of DEX to ADR-925 in vitro (primary cardiomyocytes) and in vivo (rabbits) under conditions where DEX is clearly cardioprotective against anthracycline cardiotoxicity. " 01/01/2000 - "It has been suggested that its hydrolysis product, ICRF-198, chelates and removes free iron and iron associated with doxorubiciniron complex and, therefore, prevents the formation of free radical, lipid peroxidation and cardiotoxicity. " 05/25/1993 - "They also imply that .OH production may not be as important in Adriamycin cardiotoxicity as other radical reactions, such as lipid peroxidation and thiol oxidation, that are inhibited by ICRF-198." 01/01/2018 - "Dexrazoxane (DEX), the only cardioprotectant approved against anthracycline cardiotoxicity, has been traditionally deemed to be a prodrug of the iron-chelating metabolite ADR-925. " 01/01/1997 - "Dexrazoxane reduces this cardiotoxicity, possibly by removal of iron from doxorubicin by the EDTA-like hydrolysis product of dexrazoxane, ADR-925. "
2.	Neoplasms (Cancer) 08/01/2003 - "The study was undertaken to determine the metabolism of dexrazoxane (ICRF-187) to its one-ring open hydrolysis products and its two-rings opened metal-chelating product ADR-925 in cancer patients with brain metastases treated with high-dose etoposide. "
3.	Brain Neoplasms (Brain Tumor) 08/01/2003 - "The study was undertaken to determine the metabolism of dexrazoxane (ICRF-187) to its one-ring open hydrolysis products and its two-rings opened metal-chelating product ADR-925 in cancer patients with brain metastases treated with high-dose etoposide. "
4.	Hypoxia (Hypoxemia) 01/01/2002 - "The metal chelating hydrolysis product of dexrazoxane, ADR-925, also protected myocytes from hypoxia-reoxygenation damage, although it was less effective than dexrazoxane. "

Related Drugs and Biologics

1.	Dexrazoxane (Zinecard)
2.	Anthracyclines
3.	Metals
4.	Etoposide (VP 16)
5.	Iron
6.	Doxorubicin (Adriamycin)
7.	Sulfhydryl Compounds (Thiols)
8.	Razoxane
9.	Prodrugs
10.	Free Radicals